SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trevena, Inc. (TRVN)

NEW YORK, March 15, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Trevena, Inc. ("Trevena" or the "Company") (NASDAQ: TRVN). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/trvn.

The investigation concerns whether Trevena and certain of its officers and/or directors have issued materially misleading business information to the investing public.

On February 21, 2017, Trevena revealed the clinical trial results for its morphine-alternative drug, Oliceridine, exposing that it did not have a higher tolerability or safety compared to standard morphine. Following this news, Trevena stock dropped, damaging investors.  

If you are aware of any facts relating to this investigation, or purchased shares of Trevena common stock between January 19, 2016 and February 17, 2017, you can assist this investigation by visiting the firm's site: www.bgandg.com/trvn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-trevena-inc-trvn-300424132.html

SOURCE Bronstein, Gewirtz & Grossman, LLC